undamentalytics Newsletter

Cervomed Inc. cash flow statement

In fiscal 2025, Cervomed Inc.'s operations generated −$23.4m of cash; it spent $0 on capital projects, leaving free cash flow of −$23.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cervomed Inc.: cash flow statement, annual
Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−2−12−4−1−3−7−17−23−28
Depreciation and amortisation00000————
Stock-based pay———200111
Capital spending00——00000
Free cash flow−2−12——−3−7−17−23−28
Free cash flow after stock pay————−3−8−18−25−29
Shares issued24000146——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CRDF vs CRVOCLNN vs CRVOCLDX vs CRVO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cervomed Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cervomed Inc.